Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Covington
Cerilliant
Express Scripts
Baxter
Cipla
McKinsey
Citi

Generated: April 22, 2018

DrugPatentWatch Database Preview

VUMON Drug Profile

« Back to Dashboard

Which patents cover Vumon, and when can generic versions of Vumon launch?

Vumon is a drug marketed by Hq Speclt Pharma and is included in one NDA.

The generic ingredient in VUMON is teniposide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the teniposide profile page.
Drug patent expirations by year for VUMON
Pharmacology for VUMON
Medical Subject Heading (MeSH) Categories for VUMON
Synonyms for VUMON
(5R-(5alpha,5abeta,8aalpha,9beta(R*)))-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4-6-O-(2-thienylmethylene)-beta-D-glucopyranosyl)oxy)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one
(5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naph
(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(2-thienyl)-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-
(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8
23362-13-2
29767-20-2
31514-29-1
35317-44-3
4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside
4'-Demethyl 1-O-(4,6-O,O-(2-thenylidene)-beta-D-glucopyranosyl)epipodophyllotoxin
4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin thenylidene glucoside
4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside
4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin
767T202
957E6438QA
AB0011611
AB01274729_02
AB01274729-01
AB2000293
AC1L9QDK
AKOS015896073
Ambap29767-20-2
AOB5608
C32H32O13S
CCRIS 2058
CHEMBL452231
CS-1366
D01DBQ
DB00444
Demethyl Epipodophyllotoxin Thenylidine Glucoside
EINECS 249-831-2
Epidophyllotoxin
Epipodophyllotoxin-beta-D-thenylidene-glucoside, 4'-demethyl-
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) (8CI)
FT-0080118
Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4,6-O-((R)-2-thienylmethylene)-beta-D-glucopyranosyl)oxy)-, (5R,5aR,8aR,9S)-
Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl)-oxy)-, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-
Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl)oxy)-, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-
Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-.beta.-D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)-
GTPL6843
HSDB 6546
HY-13761
I06-2040
KS-5147
LS-63999
MolPort-006-822-656
NSC 122819
NSC-122819
NSC122819
PTG
s1787
SCHEMBL3908
Teniposid
teniposide
Teniposide (USAN/INN)
Teniposide (Vumon)
Teniposide [USAN:BAN:INN]
Teniposide [USAN:INN:BAN]
Teniposido
Teniposido [INN-Spanish]
Teniposidum
Teniposidum [INN-Latin]
Tenoposide
tho[2,3-d][1,3]dioxol-6(5aH)-one
UNII-957E6438QA
Vee M-26
Veham-Sandoz
Vehem
VM 26
VM-26
VM-26 (TN)
Vumon (TN)
Vumon, VM-26, Vehem, NSC 122819, Teniposide
Vumon;VM-26;Vehem;NSC 122819
W-5144
ZINC4099009

US Patents and Regulatory Information for VUMON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hq Speclt Pharma VUMON teniposide INJECTABLE;INJECTION 020119-001 Jul 14, 1992 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Citi
Medtronic
McKinsey
Daiichi Sankyo
Cipla
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.